ADA TV asked attendees of the 76th Scientific Sessions in New Orleans, Louisiana how the association has meaningfully influenced their life and career.
ADA TV was pleased to talk to the American Diabetes Association’s CEO, Kevin L. Hagan, about some exciting new initiatives underway.
ADA TV highlights this important session held on Sunday, June 12 at the 76th Scientific Sessions in New Orleans, Louisiana. The Chair of the session, Matthew Haller, MD, MS-CI, talked to ADA TV about the key takeaways.
Tamas L. Horvath, DVM, PhD, talked to ADA TV about being the recipient of the prestigious Outstanding Achievement Award and his talk, titled, “Hunger-promoting Hypothalamic Neurons Control Systemic Metabolism and Drive Complex Behaviors and Longevity,” at the 76th Scientific Sessions in New Orleans, Louisiana.
Sheri R. Colberg-Ochs, PhD, FACSM, talks to ADA TV about her work to lead the way in shaping physical activity guidelines for the American Diabetes Association among other organizations and why HIIT is not ideal for all diabetes patients.
It was standing room only at this popular session at the 76th Scientific Sessions in New Orleans. ADA TV interviewed the Chair, Martha L. Campbell Thompson, DVM, PhD, about the key points of the session – and we also gathered takeaways from attendees.
ADA TV talks to the American Diabetes Association’s President of Health Care & Education, Margaret “Maggie” Powers, PhD, RD, CDE, about the need to make diabetes patients aware of the importance of education and also make that education more accessible.
ADA TV checks out a few popular spots in the French Quarter that #2016ADA attendees can check out between sessions at the convention center.
ADA TV talks to Chief Scientific & Medical Officer, Robert E. Ratner, MD, FACP, FACE, about some of the exciting things being unveiled at this year’s annual meeting in New Orleans, Louisiana.
ADA TV was honored to interview Barbara B. Kahn, MD – this year’s recipient of the prestigious Banting Award. We ask Dr. Kahn about her lecture, “Adipose Tissue, Inter-Organ Communication, and the Path to Type 2 Diabetes” - as well as her plans for future research.
Their uniquely holistic research program incorporates state-of-the-art technologies, therapies and education that are all aimed at improving outcomes and the quality of life for young people with Type 1 Diabetes and their families.
The Diabetic Complications research group at the University of Michigan has created an organic, integrated and novel approach to the study of so-called “microvascular” complications of diabetes, the complications that primarily lead to the excess morbidity and mortality of diabetes.
For the past decade, this team has built its investigations upon direct evidence from humans with these complications, using novel “systems biology” and bioinformatics tools to identify the critical molecular abnormalities for each complication: nephropathy, neuropathy and retinopathy. This ability to identify major new players in the complex progression of these diseases has allowed the group to confirm their importance in disease models and to test the ability of novel treatments to reverse or prevent these devastating complications.
The complementary expertise and highly interactive style of the researchers, has allowed the University of Michigan Medical School to move from bedside to bench and back to bedside with new diagnostic and therapeutic tools that will help all patients with diabetes better understand their individual risks and how to treat and prevent diabetic retinopathy, neuropathy and nephropathy.
The goals of the San Diego Biomedical Research Institute (SDBRI) are to: Identify individuals who are at risk of either developing a disease or progressing to a new disease stage so that they can be selected for therapy. Identify which at risk individuals will be responsive to specific therapies and which will not. And to determine why some at risk individuals are not good candidates for specific therapies and develop interventions that increase sensitivity to treatment.The SDBRI have recently identified a combination of markers in the blood of children newly diagnosed with type 1 diabetes that will predict whether the patient will require a low or a high dose of insulin to maintain normal blood glucose levels. The work is published in the journal Clinical Immunology. The clinical relevance is that patients who have a blood glucose that is easier to control might be more responsive to immunotherapy to reverse disease.One of their new programs is focused on identifying molecules in the blood that are responsible for making patients who are obese more susceptible to cancer.
Our aim is to ease the burden of diabetes and improve the lives of our patients and their families through compassionate and individualized management with emphasis on education, empowerment, and use of advanced technologies. - See more at: http://madisonclinic.ucsf.edu/#sthash...